A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
Phase of Trial: Phase III
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Arbaclofen (Primary)
- Indications Muscle spasticity
- Focus Registrational; Therapeutic Use
- Acronyms OS440-3004
- Sponsors Osmotica Pharmaceutical
- 05 Mar 2018 Planned End Date changed from 1 Jan 2019 to 1 Apr 2019.
- 05 Mar 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
- 05 Mar 2018 Status changed from not yet recruiting to recruiting.